EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease

Xiaoling Li, Junjie Zhang, Bo Wei, Huan Tong

Frontiers in Pharmacology · 27.03.2026 · 17

DOI: 10.3389/fphar.2026.1775516 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Pharmacology, online erschienen am 27.03.2026. Verfasst von Xiaoling Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China. Die Arbeit nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Key Research and Development Program of Sichuan Province, Chengdu Science and Technology Bureau.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Nonalcoholic fatty liver disease (NAFLD) has become a major public health concern. Peroxisome proliferator-activated receptors (PPARs) are nuclear receptor transcription factors. PPARs are categorized into three subtypes: PPARα, β/δ, and γ. Three subtypes of PPARs play crucial roles in lipid and glucose metabolism, inflammation and fibrosis. This review summarizes randomized controlled trials on the use of PPAR agonists in the treatment of NAFLD. PPARα and PPARβ/δ agonists control circulatory lipids well, but they do not yield enough liver benefits. PPARγ agonists, particularly pioglitazone, are recommended for NAFLD treatment. PPARα/γ agonists and PPARα/β/γ agonists are plausible in the treatment of NAFLD. More clinical studies are still in need to properly unveil the efficacy of PPAR agonists in the treatment of NAFLD.

Schlagwörter

Stichwörter der Autor:innen

clinical efficacynonalcoholic fatty liver diseasenonalcoholic steatohepatitisperoxisome proliferator-activated receptorrandomized controlled trial

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, West China Hospital, Sichuan University, Chengdu, China.
  • West China School of Medicine, Sichuan University, Chengdu, China.

Förderung

  • Key Research and Development Program of Sichuan Province
  • Chengdu Science and Technology Bureau

Zitieren

APA

Li, X., Zhang, J., Wei, B., & Tong, H. (2026). Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.1775516

Vancouver

Li X, Zhang J, Wei B, Tong H. Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.1775516

BibTeX
@article{Li2026,
  author = {Li, Xiaoling and Zhang, Junjie and Wei, Bo and Tong, Huan},
  title = {Clinical efficacy of PPAR agonists in the treatment of nonalcoholic fatty liver disease},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.1775516}
}
Kostenlos starten →